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Abstract
Introduction Outpatient parenteral antimicrobial therapy (OPAT) is considered practical, safe,
and cost-effective, but roughly 20% of all adult patients on OPAT experience an adverse event
(AE). Frequency of AEs and healthcare utilization, defined as emergency department visits and
infectious disease office visits, phone calls, and emails, may be greatest in the first two weeks of
OPAT. Given that older adults (age ≥ 65) have greater cognitive decline, ADL limitations, and
comorbidities than younger adults, we sought to evaluate the frequency and timing of AEs in
older adults on OPAT. We examine patients on OPAT at Yale New Haven Hospital (YNHH)
under the hypotheses that 1) older adults will have a greater frequency of AEs and healthcare
utilization than younger adults, and 2) older adults will have AEs earlier than younger adults.
Methods We collected all data from the electronic medical record system, Epic, for YNHH. On
505 probable OPAT courses flagged and abstracted from Epic from October 2016 through
September 2017, we reviewed medical records to assess patient, infection, and OPAT
characteristics, as well as AEs and healthcare utilization. Data analysis on 457 unique OPAT
courses ≤100 days was conducted using SAS, R, and SaTScan.
Results Older and younger adults did not significantly differ in the frequency of OPAT-specific
AEs (unadjusted IRR=0.91 [0.60, 1.37], adjusted OR=0.98 [0.61, 1.57]) or frequency of
healthcare utilization (IRR=1.09 [0.90, 1.33]). Older adults have the greatest risk of OPATspecific AEs from days 4-15 after discharge (p=0.01), and younger adults’ greatest risk is from
days 5-25 (p=0.03).
Conclusion Older adults do not significantly differ in OPAT-specific AEs and healthcare
utilization compared to younger adults. Older adults seem to have a more specific risk period, so
more attention may be necessary during this time. OPAT remains a safe option for older adults.
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Introduction
Outpatient parenteral antimicrobial therapy, or OPAT, is thought to be a practical, safe,
and cost-effective mechanism to administer long-term antimicrobial therapy for patients with
severe infections.1 Previous studies have shown that the home environment leads to quicker
psychological and physical recovery, and movement of intravenous (IV) antimicrobial treatment
to the outpatient setting can reduce patient care costs by up to 70%.2
However, approximately 20% of adult patients undergoing OPAT experience adverse
events (AEs), and a significant proportion of these are serious AEs, or AEs which lead to
hospital readmission or discontinuation of an antimicrobial course.2,3,4 Examples of common
AEs resulting from IV antimicrobial treatment include skin rash, nausea/vomiting, pain at the
catheter insertion site, and fatigue. Predictors for readmission include infection recurrence or
progression, central catheter issues,5 prior hospital admission within the previous 12 months,
infection with a resistant organism, use of certain antimicrobials (primarily aminoglycosides,
vancomycin, and ß-lactams6), and increased age.7 Also, prior AEs that are less serious, such as
renal or vestibular toxicity, leukopenia, and hepatic events, are predictors of the development of
more serious AEs.4,5
The length of OPAT varies, but averages 20 days after discharge for most infectious
diagnoses.8 Clinical treatment of endocarditis, on the other hand, is typically comprised of 2
weeks of treatment in hospital and 4 weeks of outpatient treatment. Patients are at greatest risk
of developing an AE in their first two weeks of OPAT,9 suggesting that patients receiving OPAT
may require increased support at the beginning of the OPAT period. Increased support may be
manifested as increased healthcare utilization, defined as number of phone calls, office visits,
additional ED visits, and/or additional hospitalizations. More frequent follow-up visits may
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reduce patient confusion or the AEs that are causing these utilization events. Few studies have
evaluated healthcare utilization in OPAT as a marker for increased patient need, and this
information may reveal points in time where increased patient contact is necessary.9 Due to a
lack of recommendations from the Infectious Diseases Society of America (IDSA) for the
frequency of OPAT patient follow-up, this judgement is primarily left to the provider.4 IDSA
guidelines do state, however, that patients with life-threatening infections, such as endocarditis
and meningitis, may require more frequent follow-up.4
AEs of OPAT have been well-classified among adults, but few reports have specifically
examined the unique circumstances of older adults (aged ≥65 years) receiving OPAT.8 It is
currently unknown whether certain AEs of OPAT are more common or equivalent in frequency
compared to younger adults. Older adults on OPAT may experience a greater frequency of AEs8
and healthcare utilization than younger adults due to a higher prevalence of cognitive
impairment, comorbid conditions such as diabetes or chronic kidney disease, or other functional
impairments, rather than from the OPAT course itself. After controlling for relevant
comorbidities, a difference in AEs and healthcare utilization between older and younger adults
may suggest the necessity of increased support for older patients.
Conversely, older adults may not differ from younger adults in terms of AEs and
healthcare utilization during OPAT, implying that they do not have different care requirements in
terms of the OPAT course, and discharge to a nursing facility may be unnecessary. This idea is
important because Medicare does not reimburse patients for home-administered OPAT, but they
do cover nursing home stays for OPAT. If older adults do not need the increased care provided
by a nursing home, Medicare’s differential coverage of therapy location may not be beneficial.
Because little has been done to evaluate the safety of OPAT in older adults, it is important to
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measure differences in older adult populations versus younger adult populations in order to
advise best practice in infectious disease clinics.8
Gaining age-specific information on OPAT safety and care needs may greatly improve
outcomes for patients discharged on OPAT. Optimizing OPAT may reduce the number of
patients on multiple or long antimicrobial courses and their likelihood of being readmitted.7,10
Shortening and simplifying antimicrobial courses may reduce the emergence of multi-drug
resistant pathogens, alterations to the gut microbiome, and the incidence of healthcare-associated
infections.10,11
This longitudinal cohort study seeks to evaluate the frequency of AEs and healthcare
utilization in older adult patients (age ≥ 65 years) in comparison with younger adult patients (age
< 65 years) undergoing OPAT, as well as to establish a time frame where AEs are most likely to
arise in each age group. We hypothesize that 1) older adults will experience a greater frequency
of OPAT-specific AEs and healthcare utilization than younger adults, and 2) older adults will
have OPAT-specific AEs earlier in the OPAT course than younger adults.

Methods
The protocol for this project was reviewed by the Yale Human Investigative Committee
and was deemed to be a quality improvement project.
Data collection
Data for this project was obtained from Epic, the electronic medical record system for
Yale New Haven Hospital (YNHH), via 1) data abstraction by the Joint Data Analytics Team
(JDAT) at YNHH and 2) medical record reviews. Data was obtained for all adults, aged 18 and
older, discharged on OPAT from YNHH for a hospital admission beginning October 1, 2016
through September 30, 2017.
7

Our reference dataset, provided by JDAT, included all patients with an OPAT flag in
their medical chart during the given time frame. From this reference dataset, we observed which
medications patients were discharged on. Many patients with an OPAT flag were not actually
noted to be discharged any IV antiinfective, so we restricted the reference dataset to those that
did have an IV antiinfective listed, and we defined these courses as “probable OPAT courses”.
Based on medical record review of each patient with a probable OPAT course, we confirmed
whether patients were truly discharged on intravenous antiinfectives (antimicrobials, antivirals,
and antifungals). We limited the dataset to the first course noted for each individual; there were
29 subsequent courses for patients which were removed. We also restricted our patient
population to those with OPAT courses lasting ≤ 100 days, as longer courses likely suggest
inherent differences in OPAT indication and treatment. See Figure 1 for more detail.
Figure 1. Inclusion criteria flowchart

OPAT course
flagged
Nobs = 740

Probable OPAT
courses
Nobs = 505

First confirmed
OPAT course,
length ≤ 100 days
Nobs = 457

Older adults
Nobs = 204
Younger adults
Nobs = 253

The reference dataset provided information on patient demographics, insurance coverage
(i.e., Medicare vs. private), and comorbidities. We focused on comorbidities that would be most
relevant to OPAT (i.e., diabetes mellitus, chronic kidney disease, peripheral vascular disease, and
dementia). Chronic kidney disease has been noted to be associated with OPAT AEs,12 and
antimicrobials, such as vancomycin, can be nephrotoxic13 with effects exacerbated by CKD.
Previous studies have associated peripheral vascular disease and diabetes with increased
recurrence of osteomyelitis due to an inability to achieve therapeutic antimicrobial
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concentrations in infected sites.14,15 Additionally, peripherally-inserted central catheters have
been associated with deep vein thrombosis,16 and the presence of peripheral vascular disease
could precipitate this complication. A certain level of cognitive function is necessary for
OPAT17 because, at a minimum, an individual must be able to live with a central line for an
extended period of time. Patients with dementia may be at increased risk of OPAT-specific
AEs18,19 because they are more likely to touch or pull out central lines, causing dislodgement,19
or be non-compliant with administration. Based on ICD-10 codes in the reference dataset, we
noted whether a patient had diabetes, chronic kidney disease, peripheral vascular disease, or
dementia.20,21
We performed a chart review on each probable course identified in the reference dataset
(n=505). We followed each patient from discharge through 30 days after OPAT discontinuation.
If a patient had multiple OPAT courses within this time period, follow-up was extended through
30 days past discontinuation of the last course. If a patient had multiple OPAT courses outside
of this period, we only included the first course in analysis. Data collected from medical record
review include: initial admission/discharge dates, additional admission/discharge dates, physical
therapy encounters, discharge location recommendations, specimen data, date of initial infectious
disease consult, type of infection, OPAT antimicrobial data, dates of adverse events that could
not be determined from laboratory data, and dates of healthcare utilization.
Healthcare utilization was defined as any ED visit, ID office visit, or ID phone call or
email made by the patient or on behalf of the patient. ED visits represent both singular
encounters and those leading to hospital admission. For this reason, we did not include
additional hospitalizations as a variable, as they were already accounted for. OPAT-specific AEs
are listed in Supplementary Table 1. We chose to focus on those AEs that could be directly
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attributable to the OPAT course in order to produce the most specific conclusions. We chose to
exclude non-specific AEs, such as gastrointestinal events, that could be attributable other causes.
When defining first courses of antimicrobial therapy, infection type, and organisms
identified (Results, Table 2), many patients had multiple entries. For example, a patient’s first
course of antimicrobial may have been vancomycin and piperacillin-tazobactam. A patient may
have been treated for both osteomyelitis and endocarditis. They may have had both MRSA and
Pseudomonas species isolated from the infection site. We accounted for multiple antimicrobials
prescribed, then described the four most common chosen for all patients. For vancomycin, we
separated singular therapy and combination therapy. For ceftriaxone, unasyn, and oxacillin, we
listed the number of singular and combination therapies, excluding any with vancomycin (there
were no instances where ceftriaxone, unasyn, or oxacillin were used together). We accounted for
all infection types, and in this stratification, a patient with both osteomyelitis and endocarditis
would have each infection counted separately, so the total number of infection types exceeds the
number of unique patients in each age group. Similarly, we listed all organisms identified for all
infection types, and the total number of organisms isolated also exceeds the number of unique
patients. We determined which antimicrobials were attributable to each AE by whether the AE
occurred during or within the 30 days after the final day of administration of that antimicrobial.
Data analysis
Data processing was performed using Excel and SAS 9.4. Descriptive statistics, outcome
stratification, and logistic regression modeling were done using SAS. Incidence rate ratios
(IRRs) and confidence intervals were calculated using R. The denominator for IRRs was the
number of OPAT-days in the patient population, defined as days until the first OPAT-specific
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AE or total patient follow-up time for those not experiencing an AE. SaTScan was used to
reveal significant periods where patients were at risk for AEs.
We chose to perform multivariable testing to predict the relationship between older age
and OPAT-specific AEs in order to accurately control for relevant independent variables. A
logistic regression model predicting OPAT-specific AEs was created based on univariate testing
of demographic and descriptive OPAT variables at p < 0.1 significance (Supplementary Table 2).
Significant variables from univariate testing were: OPAT length > 28 days; having ≥ 1
comorbidity (i.e., chronic kidney disease, diabetes, peripheral vascular disease, and dementia);
discharge on vancomycin therapy; discharge on oxacillin therapy; indication of bone and joint
infection; and indication of skin and soft tissue infection (SSTI). We removed SSTI during
model formation because there were only 2 patients with an OPAT-specific AE and an SSTI.
These variables were then used in the logistic regression model with the binary variable for older
age.
To estimate the timing of patient risk for OPAT-specific AEs, we used SaTScan.
SaTScan is a software used primarily in public health surveillance to detect clustering of disease
cases in space and/or time. We chose to use SaTScan over a Chi square test because SaTScan
does not require pre-defined cluster periods as a Chi square test requires. In other words, a Chi
square test would force us to separate the data into increments, and we would test whether each
defined increment had a significantly greater number of adverse events than expected. SaTScan
examines all possible clustering factors from fifty percent of the provided time period down to
the day level, so it should define significant risk periods more specifically. We used the Poisson
temporal-only analysis for this data since there is no spatial importance to AE emergence.
Temporal analysis in SaTScan searches for higher numbers of cases than expected in all possible
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time windows in a given time frame. Prior studies have used the temporal-only analysis in
SaTScan to identify clusters of antibiotic-resistant infections in hospitals,22 as well as to detect
abnormal numbers of intussusception cases after the monovalent rotavirus vaccine.23 SaTScan
requires the input of dates, not simply timing to events, so we fabricated an arbitrary timeline for
patient AEs from January 1, 2017 to May 21, 2017 (reflecting AEs emerging from Day 0 through
Day 140 after discharge) using time to OPAT-specific AE. With this method, an OPAT-specific
AE occurring on day 45 after discharge would be equivalent to February 15, 2017. We set time
precision to 1 day, chose the retrospective, purely temporal version of analysis, used Poisson
descriptive statistics, scanned for areas with high rates, and aggregated by time interval of one
day. We scanned for significant clusters from Day 0 to Day 140 for patients of all age groups,
then by older and younger age groups. This identified large clusters of varying sizes for each age
stratification, so we refined the date range to these large clusters (days 1-38 for all ages, days 140 for older adults, and days 2-47 for younger adults), and performed the analysis again to
identify a more specific cluster for each group.
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Results
Descriptive Characteristics
Table 1. Descriptive characteristics of patients enrolled in outpatient parenteral antimicrobial
therapy following discharge from YNHH between October 2016 and September 2017.
Older Adults
Younger Adults
(age < 65 years)
(age ³ 65 years)
n=253
n=204
p-value a
Age, median (IQR)
Male sex, n (%)
Race, n (%)
White
Black
Other
Unknown

75.0 (69.0, 81.0)
128 (62.75)

54.0 (45.0, 59.0)
149 (58.89)

165 (80.88)
32 (15.69)
4 (1.96)
3 (1.47)

188 (74.31)
37 (14.62)
25 (9.88)
3 (1.19)

Ethnicity, n (%)
Not Hispanic
198 (97.06)
224 (88.54)
Hispanic
5 (2.45)
26 (10.28)
Unknown
1 (0.49)
3 (1.19)
Comorbidities, n (%)
Diabetes mellitus
67 (32.84)
53 (20.95)
Chronic kidney disease
62 (30.39)
42 (16.60)
Peripheral vascular disease
44 (21.57)
29 (11.46)
Dementia
10 (4.90)
0
Discharge disposition, n
(%)
Nursing home
143 (70.10)
104 (41.11)
Home, self-care or with
50 (24.51)
127 (50.20)
services
Inpatient rehab/admission
9 (4.41)
15 (5.93)
Hospice
2 (0.98)
1 (0.40)
Missing
0
6 (2.37)
Hospital Length of Stay,
9.0 (6.0, 14.0)
10.0 (6.0, 17.0)
median (IQR)
a
Chi-square test as appropriate; cells with less than 5 entries were omitted.

0.40
<0.01

<0.01

<0.01
<0.01
<0.01
<0.01
<0.01

The study population was comprised of 204 older adults and 253 younger adults. Median
age for older adults was 75 years, and that of younger adults was 54 years. The majority (~60%)
of patients were male in both age groups. Most patients in both age groups were white, but
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younger adults had a more diverse racial distribution (p<0.01). We observed a similar
relationship with non-Hispanic ethnicity (p<0.01). Older adults were more likely to have chronic
kidney disease, diabetes, peripheral vascular disease, and dementia than younger adults (p<0.01
for all four). Older adults were most likely to be discharged to a nursing home (70.1%), with a
lesser proportion discharged to their homes (24.5%). Younger adults had a more even
distribution of discharge location with 41.1% discharged to a nursing home and 50.2%
discharged to home. The median initial length of hospital stay was comparable between the two
groups at 9-10 days.
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OPAT Course
Table 2. Characteristics of outpatient parenteral antimicrobial therapy episodes among patients
discharged from YNHH between October 2016 and September 2017.
Older Adults
Younger Adults
(age <65 years)
(age ³ 65 years)
n=253
n=204
p-value a
Length on OPAT, median (IQR)
31.0 (17.0, 38.0)
33.0 (22.0, 38.0)
OPAT course > 28 days, n (%)
111 (54.41)
151 (59.68)
0.26
First course of antimicrobial, n (%)
0.88
Vancomycin
58 (28.43)
83 (32.81)
Vancomycin combination
39 (19.12)
46 (18.18)
b
Any ceftriaxone combination
36 (17.65)
36 (14.23)
b
Any unasyn combination
13 (6.37)
15 (5.93)
b
Any oxacillin combination
11 (5.39)
16 (6.32)
Other
47 (23.04)
57 (22.53)
Infection type, n (%) c
0.41
Osteomyelitis
61 (26.87)
96 (34.41)
Endovascular infection d
39 (17.18)
36 (12.90)
d
Bone and joint infection
33 (14.54)
32 (11.47)
Central nervous system infection
22 (9.69)
25 (8.96)
Skin and soft tissue infection
10 (4.41)
15 (5.48)
Other
62 (27.31)
75 (26.88)
Organism, n (%)
<0.01
MRSA
32 (8.49)
65 (14.04)
MSSA
36 (9.55)
49 (10.58)
Hemolytic Streptococcus
21 (5.57)
29 (6.26)
Enterococcus faecalis
32 (8.49)
13 (2.81)
Oral Strep spp
24 (6.37)
22 (4.75)
Corynebacterium spp
15 (3.98)
27 (5.83)
Pseudomonas spp
17 (4.51)
24 (5.18)
Other
200 (53.05)
234 (50.54)
a
Chi-square test as appropriate; cells with less than 5 entries were omitted.
b
All combinations excluded combinations with vancomycin.
c
Patients may have had more than one infection type or organism indicated. These values are
the sum of all infection types/organisms isolated in all patients on OPAT, so their total may sum
to greater than the number of patients in the study.
d
17.33% of endovascular infections were primary bacteremia; the remainder were endocarditis.
67.69% of bone and joint infections were prosthetic joint infections.
Median length of OPAT course was 31 days for older adults and 33 days for younger
adults. Over half of both age groups had a course lasting longer than 28 days (p=0.26). The
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choice of antimicrobial for the OPAT course was no different between older and younger adults
(p=0.67). Vancomycin alone or vancomycin given with other antimicrobials was the most
common antimicrobial regimen prescribed, followed by ceftriaxone or a ceftriaxone
combination, unasyn/unasyn combination, and oxacillin/oxacillin combination, as well as a few
other antimicrobials such as piperacillin-tazobactam, cefazolin, daptomycin, and ceftazidime.
The most common indication in both age groups was osteomyelitis, followed by endovascular
infection, bone and joint infection, central nervous system infection, and skin and soft tissue
infection, as well as others including genitourinary tract infection and intraabdominal infection.
The most common organisms isolated in this population included methicillin-resistant
Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus, hemolytic Streptococcus
species, Enterococcus faecalis, oral Streptococcus species, Corynebacterium species, and
Pseudomonas species. The distribution of organisms isolated differed between older and younger
adults (p<0.01).
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OPAT-Specific Adverse Events
Table 3. OPAT-specific adverse events in patients discharged on outpatient parenteral
antimicrobial therapy from YNHH between October 2016 and September 2017.
Older Adults
Younger Adults
(age < 65 years)
(age ³ 65 years)
n=253
n=204
p-value a
Percent having at least one
42 (20.59)
63 (24.90)
OPAT-specific adverse
event, n (%)
Time in days to OPAT12.0 (7.0, 28.0)
19.0 (10.0, 32.0)
specific AE, median (IQR)
Most common
antimicrobials attributable
to first OPAT-specific AE
Vancomycin
21 (33.87)
42 (36.84)
Ceftriaxone
8 (12.90)
13 (11.40)
Oxacillin
6 (9.68)
7 (6.14)
Other
27 (43.55)
52 (45.61)
a
Chi-square test as appropriate; cells with less than 5 entries were omitted.

0.28

0.67

20.6% of older adults experienced an OPAT-specific AE during OPAT therapy or within
the 30 days after OPAT discontinuation, and 24.9% of younger adults experienced an OPATspecific AE during this time frame (p=0.26). The median number of days to an OPAT-specific
AE was 12 for older adults and 19 for younger adults. The majority of OPAT-specific AEs were
attributable to vancomycin, ceftriaxone, or oxacillin, and the distribution of attributable
antimicrobials did not differ between older and younger patients (p=0.67). The incidence rate of
OPAT-specific AEs was not statistically different between older and younger patients
(IRR=0.91, Table 5).
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Healthcare Utilization
Table 4. Healthcare utilization in patients discharged on outpatient parenteral antimicrobial
therapy from YNHH between October 2016 and September 2017.
Older Adults
Younger Adults
(age < 65 years)
(age ³ 65 years)
n=253
n=204
p-value a
Total healthcare utilization
Percent having at least one
189 (92.65)
231 (91.30)
healthcare encounter, n (%)
ED visits
Percent having at least one
77 (37.75)
85 (33.60)
ED visit, n (%)
ID office visits
Percent having at least one
140 (68.63)
191 (75.49)
ID office visit, n (%)
Time to first ID office visit,
32.0 (20.5, 39.0)
34.0 (23.0, 40.0)
median (IQR)
a
Chi-square test as appropriate; cells with less than 5 entries were omitted.

0.60
0.36
0.10

Over 90% of both age groups had at least one healthcare encounter over their follow-up
periods (p=0.60), over 30% had at least one emergency department visit (p=0.36), and
approximately 70% had at least one office visit with the infectious disease department at YNHH
(p=0.10). The median number of days to their first ID office visit (older=32, younger=34)
corresponds with YNHH’s general practice of scheduling an office visit at the end of OPAT to
ensure treatment effectiveness. There was no difference in the percentage of older and younger
adults having at least one instance of healthcare utilization overall, ED visit, or office visit. The
rate of overall healthcare utilization between older and younger patients was not significantly
different (IRR=1.09, Table 5).
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Table 5. Crude incidence rate of OPAT-specific adverse events and healthcare utilization per
1,000 OPAT-days at risk, per age group.
Older Adults
Younger Adults
IRR (95% CI)
(age < 65 years)
(age ³ 65 years)
n=253
n=204
OPAT-specific AEs
77.05
84.68
0.91 (0.60, 1.37)
Healthcare utilization
26.07
23.83
1.09 (0.90, 1.33)

Multivariable Analysis
Table 6. Adjusted odds ratios estimated by logistic regression model a predicting ≥ 1 OPATspecific adverse event.
Independent variable
OR Estimate
95% CI
Older age
0.98
(0.61, 1.57)
OPAT length > 28 days
1.62
(1.00, 2.64)
Presence of ≥ 1 comorbidity
0.46
(0.28, 0.76)
Vancomycin during initial
1.92
(1.18, 3.12)
OPAT course
Oxacillin during initial OPAT
3.32
(1.51, 7.30)
course
Bone and joint infection
1.51
(0.82, 2.76)
a
Logistic regression model created based on univariate testing of demographic and OPAT
variables’ association with OPAT-specific AEs at p < 0.1 significance (Supplementary Table 2).
After controlling for variables found to be associated with OPAT-specific AEs with
univariate testing (Supplementary Table 2), patients age ≥ 65 years had 0.98 (0.61, 1.57) times
the odds of developing an OPAT-specific AE than patients age < 65 years. Based on the 95%
confidence interval, this association was not significant. Other control variables were
significantly associated with OPAT-specific AEs. Having ≥ 1 comorbidity was associated with
having 0.46 times the odds of developing an OPAT-specific AE than that of having no
comorbidities. Vancomycin administered during the first course was associated with greater
odds of developing an OPAT-specific AE, and we observed a similar association with oxacillin
administration.
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Physical Therapy
Table 7. Physical therapy (PT) recommendations of older and younger patients with Medicare
discharged to SNFs on outpatient parenteral antimicrobial therapy.
Older Adults a
Younger Adults a
(age < 65 years)
(age ³ 65 years)
n=111 b
n=90 b
Discharge to
No discharge
Discharge
No discharge to
SNF
to SNF
to SNF
SNF
PT recommended SNF,
52 (91.23)
5 (8.77)
13 (92.86)
1 (7.14)
n (% per
recommendation)
PT did not recommend
14 (48.28)
15 (51.72)
2 (16.67)
10 (83.33)
SNF, n (% per
recommendation)
a
95.56% of older patients who had a PT encounter were on Medicare; we subsetted older
patients to the Medicare population. 23.42% of younger patients who had a PT encounter were
on Medicare; we subsetted younger patients to the smaller Medicare population.
b
Not all patients had a PT encounter during their initial hospitalization. Additionally, the
location of PT notes in the Epic system was inconsistent, which may have led to missed PT
encounters during medical record reviews. This may have led to an underestimation of the
number of patients with PT encounters, but we do not expect that this biased the results
presented because discharge recommendation is our outcome of interest, not whether a patient
had a PT encounter.
Among older adults for whom physical therapy did not recommend discharge to a
nursing facility, 45.2% were still discharged to a nursing facility. Among younger adults, 16.7%
were discharged to a nursing facility when physical therapy did not recommend it.
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Temporal Trends in Adverse Events
Figure 2. Timing of OPAT-specific AEs in all ages over the course of therapy.

8
Number OPAT AEs

7
6
Older Adults

5
4

Younger Adults

3
2
1
0

Day

Day 30
Timeline of patient exposure

Day 58

The majority of OPAT-specific AEs appear to occur in the first 45 days of OPAT in all
ages. SaTScan analysis revealed significant clusters of timing of first OPAT-specific AEs from
days 4-17 overall (p=0.01), days 4-15 for older patients (p=0.01), and days 5-25 for younger
patients (p=0.03).

Discussion
These results confirm that OPAT has similar safety implications in older adults as in
younger adults. The crude comparison of the percentage of older versus younger adults
experiencing OPAT-specific AEs, rate of OPAT-specific AEs per 1,000 OPAT-days, and
multivariable analysis of older age’s association with OPAT-specific AEs all showed no
difference in OPAT-specific AEs in older versus younger patients. We also found that patients
discharged on oxacillin or vancomycin had greater odds of developing an OPAT-specific AE
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than patients discharged on other antimicrobial regimens, adding to existing data that
vancomycin and b-lactam antibiotics may have increased consequences for patients on OPAT.6,9
Prior studies have also shown similar rates of antimicrobial change, catheter-related
complications,24 and hospital readmissions in older and younger patients.8 Additionally,
previous studies have found insignificant risk ratios for the association between AEs and older
age9 and insignificant multivariable-adjusted odds ratios of older age and AEs.8
This study is distinct from prior studies in that it provides a comprehensive analysis of
AEs that can be directly attributed to the OPAT course. Previous studies have focused on a more
general definition of AEs, and they have not included all of the OPAT-specific AEs that we did
in our definition. Our detailed review of the medical record allowed us to provide a specific
estimate of risk that we believe is attributable to the OPAT course. These results, in combination
with previous conclusions on hospital readmissions and treatment effectiveness in older and
younger patients,8,9 show that risk does not significantly differ for AEs in older compared to
younger patients on OPAT. This study also confirms prior estimates that approximately 20% of
all patients on OPAT experience at least one AE.2,3,4
ID-relevant healthcare utilization did not differ between older and younger patients.
Older adults had a higher frequency of comorbidities, but this did not translate into more
interaction with the ID team. Patients with comorbidities have been shown to exhibit increased
frequencies of general practitioner visits, specialist visits, and hospital admissions,25 but since
patients on OPAT tend to have similar infection types and OPAT characteristics (i.e., length and
antimicrobial choice), ID interaction was likely unaffected by age-related comorbidities.
Another reason that older adults did not have increased healthcare utilization may be that that
older adults were more likely to be discharged to a nursing facility. Any minor events that
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occurred would likely have been taken care of by the nursing staff and not reported to the ID
team. Other patients that are not in a nursing home may warrant a phone call or office visit.26
Interestingly, having at least one comorbidity was associated with fewer odds of OPATspecific AEs than having no comorbidities. This may also result from greater interaction with
the non-ID team and increased likelihood of being discharged to a nursing home, since more
minor AEs may have been taken care of and not reported by non-ID physicians/nursing staff,
leading to fewer odds of OPAT-specific AEs among this population with more comorbidities.
Our analysis of temporal trends in OPAT-specific AEs using SaTScan revealed
significant clustering of patients’ first OPAT-specific AEs for both age groups separately and
combined. Older adults seemed to have a more specific time period of risk (days 4-15) than
younger adults (days 5-25). This suggests that older adults are most at risk of developing an
OPAT-specific AE during approximately their first two weeks of therapy, whereas younger
adults’ risk appears more evenly distributed throughout their therapy. Related to the discussion
above, this may be explained by older adults’ higher frequency of comorbidities; they are more
likely to have regular interaction with overall health services due to other illnesses,25 and any
significant adverse event that occurs (and that is not deterred, see above) can be identified more
rapidly. Similarly, because older adults are more likely to be discharged to nursing facilities,
significant AEs may be recognized more rapidly. This study revealed SaTScan to be an
important tool outside of its typical use in large-scale surveillance activities. Additionally, we
were able to use the software’s temporal analysis to describe events that did not happen in the
same time frame by transposing patient events to an artificial timeline, and this methodology has
not yet been described in the literature. One drawback to using SaTScan to evaluate timing of
OPAT-specific AEs, however, is that it did not allow us to test whether there was a significant
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difference in OPAT-specific AEs between older and younger patients, only identifying
significant clusters within each group. Nevertheless, the methods we describe to perform this
analysis are remarkably useful in determining the timing of patient events, and SaTScan’s utility
with clinical data and unique public health data should be explored further.
In cases where physical therapy did not recommend discharge to nursing home among
Medicare beneficiaries, older adults seem to be more likely to be discharged to a nursing home
than younger adults. Medicare covers nursing home stays regardless of physical therapy
recommendation, and a greater frequency of comorbidities among older patients may result in
discharge to nursing home against physical therapy recommendation in order to ensure that their
conditions are being managed. Additionally, there may be concern for complications with
OPAT in older patients if they are discharged to home. However, discharge to a skilled nursing
facility was not significantly associated with OPAT-specific adverse events during univariate
Chi square testing (Supplementary Table 2), indicating that discharge to a nursing facility to
prevent OPAT-related AEs is not necessary. Therefore, if physical therapy determines that a
patient does not require post-discharge care at a nursing home, the administration of OPAT
should not indicate otherwise.
There are a number of limitations to this study. We relied on data from medical charts at
all stages of the project. Medical records tend to give an incomplete picture of a clinical course
due to patients’ lack of interaction with healthcare providers in the outpatient setting, incomplete
recording of relevant information by providers, other shifts in information storage, or changing
tendencies of those interacting with the medical record system. Also, there is a potential for
observation bias in this study; since we reviewed medical records retrospectively on all
observations to obtain the majority of relevant information, we could not be blinded to patient
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age, and it is possible that we searched for characteristics and outcomes differentially between
older and younger patients. We likely underestimated the risk of AEs due to OPAT because we
focused our analyses on those AEs that could be specifically related to OPAT. We did not
evaluate events such as gastrointestinal issues, allergic reactions, or laboratory-confirmed
toxicities because these were highly non-specific to OPAT, and it would be inaccurate to assume
that any instance of these AEs during OPAT through the 30 days after OPAT discontinuation
was due to the OPAT course. Most providers did not conclusively state the indication of such
AEs, and their occurrence may be due to the prevalence of comorbidities, non-OPAT
medications, and other health events in the population. Finally, this is an epidemiologic study,
and our findings alone are associations.

Conclusion
Older and younger adults discharged on OPAT experience similar frequencies of AEs,
but older adults should be monitored more carefully in the first two weeks of OPAT. Healthcare
utilization is a simple method to describe patient interaction with a healthcare system and
identify follow-up needs in a patient population, and the utility of SaTScan’s temporal-only
analysis to evaluate clinical events should be studied further. Older adults do not experience a
greater frequency of AEs in the home versus nursing home setting, so discharge to a nursing
home is unnecessary if physical therapy recommends the home setting.
OPAT is a safe option for older adults requiring IV antimicrobial therapy in comparison
with younger adults. It may be optimized further by focusing on issues of AE timing and
discharge discrepancies discussed in this study. As general OPAT practice continues to improve,
we should continue to take AE incidence, timing of AEs, and patient support needs into account.
Additionally, older adults may have the same safety considerations as younger adults on OPAT,
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but over 20% of both groups experienced at least one OPAT-specific AE. Many of these AEs
are preventable, so there are still improvements to be made in OPAT safety overall.

Supplementary Tables
Supplementary Table 1. List and definitions/justifications of collected OPAT-specific AEs.
OPAT-Specific AEs
Definition
Antimicrobial indications
Missed antimicrobial dose 27 As documented in medical record. Represents difficulty
with therapy and/or lack of attention by patient/caregiver.
9
Change in antimicrobial agent As documented in medical record. Telling of any AE
serious enough to change therapy, or lack of efficacy of
chosen antimicrobial
Early discontinuation of As documented in medical record. Telling of any AE
antimicrobial agent 9 serious enough end therapy early. Excludes cases where
antimicrobial was ended early due to infection resolution.
Vascular access complications
Dressing problem 27 As documented in medical record. Line, not wound,
dressing.
Occlusion 28 As documented in medical record.
Dislodgement 28 As documented in medical record. Either accidental
dislodgement, or patient altering the line or pulling line
out.
Thrombosis 28 As documented in medical record. Only thrombosis in
the same extremity as the line insertion site.
Broken extension As documented in medical record. No citation to
previous use of this AE, but observed during chart
reviews and clearly related to OPAT line access.
Pain or swelling (without As documented in medical record. Only at line insertion
thrombosis) 28 site or in same extremity as insertions site.
Leaking 28 As documented in medical record. From insertion site.
Bleeding 28 As documented in medical record. From insertion site.
Site infection 28 As documented in medical record.
Site itching As documented in medical record. No citation to
previous use of this AE, but observed during chart
reviews and clearly related to OPAT line complications.
Change in line 24 As documented in medical record. Represents issues
with original line.
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Supplementary Table 2. Univariate Chi square analysis of variables’ relationship with OPATspecific AEs a to create multivariable logistic regression model (Results Table 6).
Relevant Variables
p-value b
Patient characteristics
≥ 1 comorbidity
0.001
Hispanic ethnicity
0.348
White race
0.812
Male gender
0.708
Discharge to SNF
0.200
Initial LOS > 8 days
0.745
Infection characteristics
Osteomyelitis
0.155
Endocarditis/primary bacteremia
0.712
Bone and joint infection
0.054
CNS infection
0.941
c
Skin and soft tissue infection
0.067
Other infection type
0.540
Infection with MRSA
0.364
OPAT characteristics
OPAT length > 28 days
0.008
Treatment with vancomycin
0.025
Treatment with oxacillin
0.004
a
Binary variables’ relationship with binary OPAT-specific AEs (at least one AE=1; no AE=0)
b
Variables chosen at p < 0.1 significance.
c
SSTI has a significant association with the occurrence of an OPAT-specific AE, but there were
only two individuals with an SSTI and who developed an AE, so we removed this variable from
the multivariable analysis.
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